Merck reports observational data of Januvia and metformin combination for type 2 Diabetes
Merck has reported data from an observational study that assessed the differences in initiated insulin therapy in patients with type 2 diabetes taking a combination of Januvia (sitagliptin) and metformin, as well as sulphonylurea and metformin.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Janumet | Januvia | Merck | Metformin | Pharmaceuticals | Study